Tianjin TEDA Biomedical Engineering Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of biological compound fertilizer products in the People’s Republic of China. More Details
Flawless balance sheet and slightly overvalued.
Share Price & News
How has Tianjin TEDA Biomedical Engineering's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 8189 is more volatile than 90% of Hong Kong stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: 8189's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
7 Day Return
1 Year Return
Return vs Industry: 8189 exceeded the Hong Kong Chemicals industry which returned 46.4% over the past year.
Return vs Market: 8189 exceeded the Hong Kong Market which returned 24.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Tianjin TEDA Biomedical Engineering's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StTianjin TEDA Biomedical Engineering (HKG:8189) Has Debt But No Earnings; Should You Worry?
4 months ago | Simply Wall StHealth Check: How Prudently Does Tianjin TEDA Biomedical Engineering (HKG:8189) Use Debt?
8 months ago | Simply Wall StIs Tianjin TEDA Biomedical Engineering (HKG:8189) A Risky Investment?
Is Tianjin TEDA Biomedical Engineering undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 8189 (HK$0.16) is trading below our estimate of fair value (HK$0.4)
Significantly Below Fair Value: 8189 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 8189 is unprofitable, so we can't compare its PE Ratio to the Hong Kong Chemicals industry average.
PE vs Market: 8189 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 8189's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 8189 is overvalued based on its PB Ratio (1.7x) compared to the HK Chemicals industry average (0.8x).
How is Tianjin TEDA Biomedical Engineering forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Materials industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tianjin TEDA Biomedical Engineering has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Tianjin TEDA Biomedical Engineering performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 8189 is currently unprofitable.
Growing Profit Margin: 8189 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 8189 is unprofitable, and losses have increased over the past 5 years at a rate of 42.8% per year.
Accelerating Growth: Unable to compare 8189's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 8189 is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-0.7%).
Return on Equity
High ROE: 8189 has a negative Return on Equity (-29.59%), as it is currently unprofitable.
How is Tianjin TEDA Biomedical Engineering's financial position?
Financial Position Analysis
Short Term Liabilities: 8189's short term assets (CN¥260.2M) exceed its short term liabilities (CN¥194.3M).
Long Term Liabilities: 8189's short term assets (CN¥260.2M) exceed its long term liabilities (CN¥43.5M).
Debt to Equity History and Analysis
Debt Level: 8189's debt to equity ratio (10.2%) is considered satisfactory.
Reducing Debt: 8189's debt to equity ratio has reduced from 13.1% to 10.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 8189 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 8189 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 42.8% per year.
What is Tianjin TEDA Biomedical Engineering current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 8189's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 8189's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 8189's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 8189's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 8189's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Li Sun (46 yo)
Ms. Li Sun has been Chairman of the Board and Executive Director of Tianjin TEDA Biomedical Engineering Company Limited since August 20, 2015 and its Chief Executive Officer since December 30, 2019. She ha...
CEO Compensation Analysis
Compensation vs Market: Li's total compensation ($USD108.39K) is below average for companies of similar size in the Hong Kong market ($USD230.31K).
Compensation vs Earnings: Li's compensation has been consistent with company performance over the past year.
Experienced Management: 8189's management team is considered experienced (2.4 years average tenure).
Experienced Board: 8189's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Tianjin TEDA Biomedical Engineering Company Limited's company bio, employee growth, exchange listings and data sources
- Name: Tianjin TEDA Biomedical Engineering Company Limited
- Ticker: 8189
- Exchange: SEHK
- Founded: 2000
- Industry: Fertilizers and Agricultural Chemicals
- Sector: Materials
- Market Cap: HK$301.226m
- Shares outstanding: 1.89b
- Website: https://www.bioteda.com
Number of Employees
- Tianjin TEDA Biomedical Engineering Company Limited
- Tianda Hi-Tech Park
- Block A2, 9th Floor
Tianjin TEDA Biomedical Engineering Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of biological compound fertilizer products in the People’s R...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/16 10:59|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.